Browsing Tag
INFORM-MS
1 post
Tiziana Life Sciences’ multiple sclerosis breakthrough faces commercial and regulatory hurdles
Tiziana Life Sciences stock drops 16% despite positive foralumab results. Explore its $3.9M cash balance, funding risks and MS drug outlook.